OKC pharma firm acquired in deal valued up to $665 million

By admin | News | 0 comment | 22 November, 2016 | 0

OKC pharmaceutical firm acquired in deal valued up to $665 million
By Don Mecoy
Copyright © 2016, The Oklahoma Publishing Company

Some Oklahoma angel investors are getting their wings.

Those “angels,” a term for individual investors in early stage companies, will get payoffs ranging from about five times to about 20 times what they risked in the development of Oklahoma City-based Selexys Pharmaceuticals Corp.

Selexys has closed a deal to sell the company for up to $665 million to global drug giant Novartis.

Former Selexys CEO Scott Rollins said all the early investments in the company came from Oklahomans and state-based entities.

“It’s been a great story,” Rollins said Monday. “They’re all going to make a lot of money.”

Read the story at NewsOK.com.

i2E, Novartis, Presbyterian Health Foundation, Scott Meacham, Scott Rollins, Selexys, Selexys Pharmaceuticals, Tetherex, University of Oklahoma

Linear Health Sciences Announces U.S. FDA Clearance and Health Canada Approval of its Orchid Safety Release Valve (SRV)

By sarah | Comments are Closed

Device Intended to Reduce Risk of IV Catheter Failure and Replacement in Hospitals; Sister Product Orchid SRV-Type D for Drainage to Launch Simultaneously OKLAHOMA CITY, Okla. – May 17, 2022 – Medical device company LinearRead more
Student teams from OSU, TU and East Central claim Love’s Cup top awards

By sarah | Comments are Closed

May 3, 2022 Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 or email sseagraves@i2E.org Teams led by student innovators from Oklahoma State University, the University of Tulsa and East Central University claimed first placeRead more
A final column and a thank you for reading

By sarah | Comments are Closed

Thank you for reading this column for nearly a decade By Scott Meacham This is my final column for The Oklahoman. As CEO of i2E, I have had the wonderful opportunity since January 2013 to write thisRead more
A significant impact on new ventures? That’s i2E’s e3 program

By sarah | Comments are Closed

Accelerators like i2E’s e3 can have a significant impact on new ventures By Scott Meacham When the team from Zen Health Technologies formally introduces their company, they describe a business that uses immersive technologies for personalRead more
Autigen Announces Collaboration with Boehringer Ingelheim

By sarah | 0 comment

Novel Treatments for Hearing Loss Collaboration and licensing agreement to advance novel therapies for sensorineural hearing loss (SNHL), where there are currently no approved pharmacological therapies. OKLAHOMA CITY–(BUSINESS WIRE)– Autigen, a biotechnology portfolio company of theRead more

You must be logged in to post a comment.

Next Previous

OKC pharma firm acquired in deal valued up to $665 million

OKC pharma firm acquired in deal valued up to $665 million

Related Post

Linear Health Sciences Announces U.S. FDA Clearance and Health Canada Approval of its Orchid Safety Release Valve (SRV)

Student teams from OSU, TU and East Central claim Love’s Cup top awards

A final column and a thank you for reading

A significant impact on new ventures? That’s i2E’s e3 program

Autigen Announces Collaboration with Boehringer Ingelheim

Leave a Comment

Oklahoma City Office

Tulsa Office